SHPMY vs SR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SHPMY · SHANGHAI PHARMACEU$7.26 ▲ 0.00%
SR · Spire$88.81 ▼ 0.48%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SHPMY -7.7%
- SR +3.2%
Head to head
| Metric | SHPMY | SR |
|---|---|---|
| Price | $7.26 | $88.81 |
| Change today | ▲ 0.00% | ▼ 0.48% |
| Market cap | $5.25B | $5.25B |
| Return, 3 months | -1.8% | +10.7% |
| Return, year to date | -7.7% | +10.6% |
| Return, 1 year | -7.7% | +3.0% |
| P/E (TTM) | 7.2 | 9.9 |
| P/B | 0.5 | 1.5 |
| P/E percentile vs own 5y | – | 5th |
| Dividend yield | 4.57% | 3.67% |
| Revenue growth (YoY, latest qtr) | – | +19.2% |
| Net profit growth (YoY) | – | +910.5% |
| Gross margin | – | 43.0% |
| Operating margin | – | 21.7% |
| Net margin | – | 19.9% |
| Return on equity | – | 15.6% |
| Analyst target vs. price | – | +1.9% |
| Analyst buy share | – | 50% |
| RSI (14) | 67 | 68 |
| 30-day volatility | 31.4% | 18.4% |
| Max drawdown, 1 year | -18.5% | -19.4% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SR is the largest of the group by market value.
- SR has returned the most over the past year.
- SHPMY carries the lowest trailing P/E.
- SHPMY pays the highest dividend yield.
- SR has been the calmest stock over the last 30 days.